Transgene SA has been waiting years to successfully catch a commercial wave with its pipeline and combination immunotherapy strategy. Its French CEO believes that this may at last be about to happen.
The France-based company, which has been in existence for nearly 40 years, is focused on virus-based immunotherapies to treat